Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 1,367 (final count)
- Started
- Dec 18, 2018
- Main results expected
- Aug 26, 2024
- Fully finished
- Apr 14, 2026
- Results posted
- Sep 12, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)
Measured over: Up to approximately 67 months
PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants
Measured over: Up to approximately 67 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03740165 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC